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ABSTRACT
Chlamydia pneumoniae respiratory tract infections were studied in 512 male military conscripts (123
asthmatic and 389 non-asthmatic) taking part in 180-day service between July 2004 and July 2005 in
Kajaani, Finland. Respiratory tract infections requiring a medical consultation were analysed
prospectively. At baseline, at end of service, and during each episode of respiratory infection, blood
samples were obtained for measurement of C. pneumoniae antibodies. Data concerning the clinical
features of each infection episode were collected. Serological evidence of acute C. pneumoniae infection
was found in 34 of the 512 conscripts with antibody data available, including 9.8% of the asthmatic
subjects and 5.7% of the non-asthmatic subjects (p 0.111). A serological diagnosis could be made for 25
clinical episodes in 24 conscripts. The spectrum of respiratory tract infections included 13 episodes of
mild upper respiratory tract infection and seven episodes of sinusitis, with ﬁve episodes involving
asthma exacerbation. Two of three pneumonias were primary infections. Primary infections were
diagnosed in ﬁve subjects, and re-infection ⁄ reactivation in 19 subjects, with the latter comprising 12 non-
asthmatic subjects and seven asthmatic subjects (p 0.180). Prolonged infections were present in six
asthmatic subjects and one non-asthmatic subject (p 0.001). A wide variety of respiratory tract infections,
ranging from common cold to pneumonia, were associated with serologically conﬁrmed C. pneumoniae
infections. Infections were often mild, with common cold and sinusitis being the most common
manifestations. Acute, rapidly resolved C. pneumoniae infections were equally common among
asthmatic subjects and non-asthmatic subjects, whereas prolonged infections were more common
among subjects with asthma.
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INTRODUCTION
Chlamydia pneumoniae has been associated with
both epidemic and endemic episodes of acute
respiratory disease [1]. Primary C. pneumoniae
infections occur mostly in children, particularly
school children [2,3], and the majority of adults
show serological evidence of past infection [4].
Recurrent or secondary respiratory tract infec-
tion can occur, even when antibodies induced
by a previous infection are still detectable in
serum [5]. A particular feature of C. pneumoniae
is its ability to cause prolonged or chronic
infection. Serology, based on the use of paired
sera, is the tool used most often for the routine
diagnosis of acute C. pneumoniae infections [5,6],
although this approach is only useful retrospec-
tively.
C. pneumoniae can cause both upper and lower
respiratory tract infection. Mild and asymptom-
atic infections are characteristic of C. pneumoniae
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[7,8], and typical infections are also characterised
by gradual onset, pharyngitis with hoarseness,
mild cough and transient fever. The disease may
have a biphasic course, with resolution of phar-
yngitis before the development of bronchitis or
pneumonia [1,2,4,9,10]. Cough is very common
and often prolonged. Central nervous system
symptoms, including headache, also seem to be
common in patients with C. pneumoniae pneumo-
nia [11].
The role of C. pneumoniae in acute bronchitis
and pneumonia is well-established. Pneumonia
caused by C. pneumoniae does not differ clini-
cally from pneumonia caused by other common
respiratory tract pathogens [11,12], and mixed
infections with other respiratory pathogens,
mainly Streptococcus pneumoniae, have also been
reported [13]. As a causative agent of acute
pharyngitis [14], C. pneumoniae seems to be
mainly a co-pathogen rather than a primary
agent [15]. Symptoms of sinus infection com-
monly occur in connection with C. pneumoniae
infections, and the organism has been isolated
from patients with purulent sinusitis and otitis
media with effusion [4]. In addition, several
chronic inﬂammatory diseases have been asso-
ciated with C. pneumoniae infection, including
cardiovascular disease, chronic obstructive
pulmonary disease and asthma [16,17]. C. pneu-
moniae infection has been associated with the
pathogenesis of both stable asthma and asthma
exacerbations [18].
The aim of the present study was to investigate
respiratory tract infections caused by C. pneumo-
niae in young asthmatic men and non-asthmatic
men who required a medical consultation during
their 180-day military service period in Kainuu
Brigade, Kajaani, Finland. Data concerning epi-
sodes of respiratory tract infection were collected
from a group of 235 military conscripts between
July and December 2004, and from a second group
of 283 conscripts between January and June 2005.
MATERIALS AND METHODS
Study subjects
In total, 892 men from two intake groups entering compulsory
military service in July 2004 and January 2005, respectively, in
Kajaani Garrison, northern Finland were eligible for recruit-
ment to the study and signed an informed consent form
allowing the use of their data for scientiﬁc purposes. All men
with medically diagnosed asthma, together with randomly
chosen men without asthma, were asked to participate. Of the
total of 892 subjects, 518 were included in the present study
based on the length of their service (180 days); these com-
prised 235 (64 asthmatic) men in the July 2004 intake group
and 283 (60 asthmatic) men in the January 2005 intake group.
The remaining 374 men with 270- or 360-day periods of service
were partly trained in other units. Six of the 518 men lacked
data concerning C. pneumoniae antibodies, and these subjects
were subsequently excluded.
At the beginning of their military service, each conscript
was asked to ﬁll in a questionnaire concerning his atopy ⁄ aller-
gies, previous respiratory tract infections and tobacco smoking
habits. Blood samples were collected at the beginning and end
of service, and in the acute and convalescent phases of each
infection episode. Conscripts were accommodated during their
service in barrack rooms for eight to ten individuals. The study
protocol was approved by the Ethics Committee of Kainuu
Central Hospital.
Asthma
A questionnaire was used to obtain information concerning
medically diagnosed asthma; this is the most commonly used
and validated method [19]. It was also possible to analyse self-
reported data concerning previous health examinations by a
physician.
Tobacco smoking
Smoking habits were classiﬁed on the basis of three questions:
(i) ‘have you ever smoked?’; (ii) ‘do you smoke daily
(cigarettes, cigars or pipe)?’; and (iii) ‘how much do you
currently smoke daily or did you smoke before cessation, i.e.,
how many cigarettes per day?’ Current smokers were deﬁned
as those who smoked daily, while non-smokers had never
smoked, or had quit smoking, or smoked only occasionally.
The cumulative lifetime consumption of cigarettes was deter-
mined in terms of pack-years (the number of cigarettes per
day · the number of years ⁄ 20).
Respiratory tract illness
Conscripts with acute or acutely aggravated respiratory tract
symptoms were checked by a nurse and examined by a
physician, if necessary, in the military primary-care clinic in
Kainuu Brigade. The episode was included in the database if a
respiratory tract infection or an exacerbation of asthma was
diagnosed by the physician. The diagnosis of respiratory tract
infection was based on symptoms and clinical ﬁndings.
Bacterial infections were diagnosed according to the recom-
mendations of the Finnish National Guidelines [20]. If neces-
sary, sinus ultrasound, sinus and chest radiography, blood
tests (C-reactive protein (CRP) and leukocytes) and throat
swabs for bacterial culture were used to help the clinician
differentiate between viral and bacterial infections. Asthma
exacerbation was deﬁned as an increase in asthma symptoms
(cough, breathlessness) or an increase in bronchodilator use
and ⁄or a reduced peak expiratory ﬂow rate and ⁄ or wheezing
on clinical examination. Mild episodes not referred to a
physician were not included in the analyses. Further consul-
tations within a 2-week period were considered as a single
episode. Symptoms, clinical ﬁndings and drug prescriptions
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were recorded. Respiratory tract diseases were categorised as
common cold, otitis, tonsillitis, sinusitis, bronchitis, pneumo-
nia or exacerbation of asthma.
C. pneumoniae serology and CRP determination
Sera were collected from all participants at the beginning and
end of service. In addition, acute and convalescent serum
samples were collected during respiratory tract infections for
the measurement of CRP and C. pneumoniae antibodies. The
samples were stored at )80C until analysed. The sera were
tested for IgG, IgA and IgM antibodies to C. pneumoniae by the
microimmunoﬂuorescence test, using puriﬁed elementary
bodies of Kajaani 6 as described previously [21,22]. All the
sera from a particular subject were tested in the same series to
minimise inter-assay variation. Four-fold serum dilutions were
used, starting from 1:32 for IgG and 1:10 for IgA and IgM. The
serum dilutions were incubated in a moisturised chamber for
1 h at 37C for IgG, overnight at 8C for IgA, and for 3 h at
37C for IgM. IgA- and IgM-positive sera were retested after
treatment with Gullsorb reagent (Gull Laboratories, Salt Lake
City, UT, USA) to avoid false-positive reactions [23,24]. The
presence of IgM antibodies in titres of ‡10 after Gullsorb
treatment was used to deﬁne evidence of primary infection,
and seroconversions suggesting acute infection were based on
a four-fold rise in IgG and ⁄ or IgA titres between consecutive
sera. Prolonged C. pneumoniae infections were deﬁned on the
basis of an elevation period of ‡2 months following an acute
rise in titre.
CRP concentrations were measured by enzyme immunoas-
say (IBL Immunobiological Laboratories, Hamburg, Germany)
according to the manufacturer’s instructions [25]. The CRP
concentration in serum was determined by interpolation from
a standard curve constructed from CRP standard solutions of
0–100 mg ⁄L. The minimum detection limit of the test was
1 mg ⁄L.
Statistical methods
Statistical analyses were performed using SPSS v.13.0 (SPSS
Inc., Chicago, IL, USA). Age comparison was performed using
Student’s t-test. Categorical variables were compared using
chi-squared or Fisher’s exact tests, as appropriate.
RESULTS
A recent C. pneumoniae infection was diagnosed
serologically in 34 (6.6%) of the 512 conscripts.
The characteristics of these 34 men are shown in
Table 1 in comparison with the characteristics of
all 512 conscripts included in the study. Twenty-
two of the men with recent C. pneumoniae infec-
tion were non-asthmatic and 12 were asthmatic,
with no signiﬁcant difference between the non-
asthmatic and asthmatic groups (5.7% vs. 9.8%,
p 0.111).
Acute primary infections with the presence of
IgM titres of ‡10 were seen in 13 men, nine
without and four with asthma. In ﬁve men, IgM
antibodies were present at the beginning of
service, suggesting scars from a previous infec-
tion, and another ﬁve men had IgM antibodies in
sera taken at the end of service, but these ten men
had no clinical illness. A clinical illness was
diagnosed in the other three men with IgM titres
‡10. In addition, acute primary infection with
clinical illness was diagnosed in two conscripts on
the basis of the IgG antibody response, as no IgG
antibodies were present in the acute phase.
Acute re-infections or reactivations of chronic
infection, with a four-fold or greater rise in IgG
antibodies, were found in 19 conscripts, including
12 (3.1%) of the 389 non-asthmatic men and seven
(5.7%) of the 123 asthmatic men (p 0.18) (one with
two episodes), and all of these subjects had a
clinical illness. Primary infections were diagnosed
in ﬁve men, three in non-asthmatic men and two
in asthmatic men. Prolonged infections were
diagnosed in one (0.3%) of 389 non-asthmatic
men and in six (4.9%) of 123 asthmatic men
(p 0.001).
The clinical picture was compatible in 24 men
(one with two episodes) with laboratory-
conﬁrmed C. pneumoniae infection. The clinical
symptoms and the diagnoses of these 25 episodes
are shown in Tables 2 and 3. Sixteen of the clinical
episodes occurred during the winter season
between September 2004 and April 2005, ten in
the July 2004 intake group, and 24 in the January
2005 intake group. Body temperature was <38C
in 22 and >38C in three infectious episodes. CRP
was £10 mg ⁄L in nine, 10–50 mg ⁄L in 12 and
>50 mg ⁄L in four episodes. Three men with upper
respiratory tract infection and two men with
sinusitis also experienced exacerbation of asthma.
Three cases of pneumonia were diagnosed, two of
Table 1. Characteristics of the 512 conscripts in 180-day















Subjects, n 512 231 281 10 24
Age, years,
mean (SD)
19.6 (0.7) 19.6 (0.8) 19.6 (0.6) 0.549a 19.4 (0.9) 19.5 (0.4)
Asthmatic, n (%) 123 (24.0) 63 (27.3) 60 (21.4) 0.119b 4 (40.0) 8 (33.3)
Current
smoker, n (%)
226 (44.8) 95 (41.7) 131 (47.5) 0.193b 4 (40.0) 9 (37.5)
aStudent’s t-test.
bChi-squared test.
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which were primary infections. Antimicrobial
agents were prescribed for 12 episodes, including
the three men with pneumonia who were pre-
scribed roxithromycin for 14 days. Men with
prolonged infection were treated for common cold
and sinusitis. The following antimicrobial agents




The clinical picture of C. pneumoniae infection
has been studied primarily during epidemic
periods [1,26–29]. The present study period (July
2004 to July 2005) can be considered to be a non-
epidemic period with respect to C. pneumoniae
infections in Finland. The number of laboratory-
conﬁrmed C. pneumoniae infections in Finland
has varied from 90 to 430 cases annually during
the past decade, being highest in 2003 and
lowest in 2006. In 2004, 245 C. pneumoniae infec-
tions were registered in Finland, and 32.2%
(79 ⁄ 245) of these infections occurred between
June and December (National Public Health
Institute, unpublished data). In 2005, 113 infec-
tions were registered, 62.8% of which occurred
between January and July. Usually, >50% of
C. pneumoniae infections occur in Finland during
winter. In the present study, 16 (47.1%) of the
clinical episodes occurred between September
2004 and April 2005.
Primary infections occur mostly during child-
hood. In the present study, primary clinical
illnesses were diagnosed in ﬁve (14.7%) young
men. A four-fold rise in C. pneumoniae IgG anti-
bodies, suggesting re-infection or reactivation of a
persistent infection, was naturally more common,
being conﬁrmed in 19 men (one with two epi-
sodes). Since C. pneumoniae, like other Chlamydia
spp., tends to cause persistent infection, serolog-
ical tests do not differentiate between re-infec-
tions and reactivation of chronic infection during
acute episodes in adults. C. pneumoniae infections
during epidemics may involve a combination
of both primary and secondary infections, and
further molecular or typing investigations are
required to determine whether a strain represents
a reactivated strain or a new infection.
C. pneumoniae has been associated with asthma
in various ways; an infection may precede
the onset of asthma, exacerbate asthma or make
the management of asthma more difﬁcult [30].
The present data revealed no statistical difference
in the number of serological diagnoses of recent
C. pneumoniae infections, or in the number
of C. pneumoniae re-infections or reactivation
episodes, between asthmatic men and non-asth-
matic men, but prolonged clinical infection with
persistently elevated IgG antibodies after an acute
C. pneumoniae episode was diagnosed in six asth-
matic men and one non-asthmatic man (4.9% vs.
0.3%, p 0.001). However, the number of pro-
longed infections was small, and further research
is required to conﬁrm the suggestion that asth-
matic individuals are prone to prolonged C. pneu-
moniae infection, although similar ﬁndings have
been published previously [31].
As reported previously, non-productive cough
is a common symptom, and fever is of low grade
[32]. In the present study, most infections were
mild, with fever of <38C in 22 episodes and CRP
values of <50 mg ⁄L in 21 episodes. It has been
estimated that c. 70% of all C. pneumoniae infec-
tions are asymptomatic [8]. In the present study,
asymptomatic infections were evidently present
in ﬁve men with IgM titres of ‡10 at the end of
their service. These individuals may have had
Table 3. Clinical diagnoses associated with 25 cases of




Common cold 13 (52)
Sinusitis 7 (28)
Tonsillitis 5 (20)
Exacerbation of asthma 5 (20)
Pneumonia 3 (12)
Bronchitis 3 (12)
Otitis media 1 (12)
aOne episode could have more than one associated diagnosis.
Table 2. Occurrence of clinical symptoms in 25 cases of













Chest soreness 1 (4)
Myalgia 1 (4)
Eczema 1 (4)
aOne episode could have more than one associated symptom.
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actual subclinical disease, or may have been so
eager to complete their service that they ignored
their symptoms.
Pneumonia and bronchitis are the most fre-
quently recognised clinical illnesses associated
with C. pneumoniae, although asymptomatic or
mildly symptomatic illness is the most common
feature of infection [4]. In the present study, 13 of
25 C. pneumoniae infections were diagnosed as
upper respiratory tract infections, with the next
most common diagnosis being sinusitis (seven
cases). Pneumonia and bronchitis were both
diagnosed in three subjects. According to previ-
ous studies, 5% of cases of bronchitis and sinus-
itis in adults are associated with C. pneumoniae
infection [4], and this organism has been isolated
from patients with purulent sinusitis and from
patients with otitis media with effusion [33]. It has
also been suggested previously that more than
one apparent aetiological agent can be demon-
strated in a majority of cases of C. pneumoniae
pneumonia [10]. Evidently, acute or chronic
infections caused by intracellular pathogens such
as C. pneumoniae may pave the way for invasion
by other bacteria, e.g., S. pneumoniae [13] and
Haemophilus inﬂuenzae [12], and some of the
patients in the present study, e.g., those with
sinusitis, might have been affected by a combina-
tion of various aetiological agents.
In the majority of respiratory tract infections,
the aetiological diagnosis remains obscure and
empirical antibiotic therapy is prescribed. Cov-
erage against atypical pathogens should be
provided for community-acquired pneumonias.
Macrolides, tetracyclines, ketolides and ﬂuoro-
quinoles demonstrate both in-vitro and in-vivo
activity against C. pneumoniae [34], but this
organism is not treatable with penicillin, ampi-
cillin and sulphonamides. In the present study,
men with pneumonia were treated with roxi-
thromycin, but those with prolonged infection
and sinusitis were prescribed antimicrobial
agents according to the recommendations for
sinusitis [35], none of which provide coverage
against C. pneumoniae. It is possible that these
men could have recovered sooner with antibiot-
ics effective against C. pneumoniae, but the use of
antimicrobial agents poses a risk for the develop-
ment of antibiotic resistance, particularly with
respect to macrolide resistance among S. pneu-
moniae [36]. The current treatment guidelines
should be followed, but additional coverage
against C. pneumoniae should be provided in
the case of prolonged infection.
In conclusion, during a non-epidemic period,
C. pneumoniae infections among adolescents
are mostly mild upper respiratory tract infections,
but the full range of clinical respiratory infections
can appear. Recent C. pneumoniae infections,
including episodes of re-infection or reactivation,
are equally frequent among asthmatic men and
non-asthmatic men, while prolonged infections
with persistent symptoms and elevated IgG levels
seem to be more common among men with
asthma than in those without asthma (p 0.001).
Further research concerning this discrepancy
during an epidemic period would be of interest.
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